ImmunoGen Switzerland GmbH

The purpose of the company is the acquisition, management, holding and disposal of intellectual property rights and the development, manufacture and marketing of pharmaceutical products, including the antibody-drug conjugates Mirvetuximab Soravtansine and Pivekimab Sunirine. The company may acquire, hold, manage and dispose of participations in companies of all kinds in Switzerland and abroad. The company may also conclude all transactions and enter into agreements that serve the company's purpose directly or indirectly or are directly related thereto. The company may grant loans or other financings to its direct or indirect parent company as well as to their or its direct or indirect subsidiaries and provide security of any kind for liabilities of such other companies, including by way of pledges on or fiduciary transfers of the company's assets or guarantees and personal securities of any kind, whether against payment or not. The company may establish branches and subsidiaries in Switzerland and abroad and acquire, hold, manage and dispose of real estate.